Drug intelligence / Profile preview

ZOC2017217

Development stage: Phase 2
Lead developer: Guangzhou Runer Ophthalmic Biotechnology
Modality: Small Molecules
Administration: Ophthalmic

Overview

ZOC2017217 is a first-in-class investigational small molecule topical eye drop (0.4% concentration) developed by Ocusun for the treatment of age-related cataracts. The drug's active ingredient is a derivative of lanosterol, a naturally occurring sterol that has been shown to reverse protein aggregation in the lens. By targeting the protein misfolding and aggregation that underlie cataract formation, ZOC2017217 aims to reduce lens opacity and improve visual function. It has completed Phase I and Phase II clinical trials in China and is undergoing a Phase II pilot study in the United States (NCT07395986).

Other names: ZOC2017217ZOC-2017217ZOC 2017217

Targets

CRY (Crystallin family)

Beyond the preview

Go deeper on ZOC2017217.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZOC2017217.

Explore the full profile